Company intelligence / Profile preview

FairJourney Biologics

Ownership: Private
Employees: ~250
Development stage: Phase 3

Overview

FairJourney Biologics is a leading global CRO specializing in end-to-end antibody discovery and development services. The company has contributed to over 14 antibodies reaching clinical trials through its clients but does not itself sponsor clinical programs. It boasts a market-leading project success rate (>99%) due to its expertise in phage display and proprietary mammalian display platforms.

Modalities: Monoclonal antibodyAntibody
Industry: Drug Discovery Services

Partnerships

Capella BioscienceargenxPartners Group (investor)GHO Capital Partners (investor)

Beyond the preview

Go deeper on FairJourney Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FairJourney Biologics.

Explore the full profile